

CAR-T- En introduksjon til teknologien og utviklingen

Eli N. Bergli


Medisinsk sjef Onkologi, Novartis Norge






CAR-T teknologien:


Hvordan virker CAR-T og hvordan fremstilles CAR-T?

Celleterapi











Hvordan fungerer CAR-T?



Lentivirus 













CAR-T-produksjon og behandling





Fremtiden for CAR-T

Fremtidens CAR-T behandling

	CURRENT	FUTURE
CONSTRUCT	 SINGLE TARGET CAR	 TCR-BASED & DUAL TARGETING
MANUFACTURING	 CENTRALIZED	 DE-CENTRALIZED, HYBRID & <i>IN VIVO</i>
CLINICAL CARE	 TODAY'S STANDARD	 IMPROVED CLINICAL CARE
CELL TYPE	 A- β T CELLS	 γ - δ T CELLS, NK CELLS & MACROPHAGES
CELL SOURCE	 AUTOLOGOUS	 ALLOGENEIC / DONOR / OFF-THE-SHELF
VECTOR	 RETROVIRAL	 GENE EDITING

